UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 49

Sortiert nach

Lacosamide in Painful Diabetic Neuropathy: An 18-Week Double-Blind Placebo-Controlled Trial

The journal of pain, 2009-08, Vol.10 (8), p.818-828

2009

Volltextzugriff (PDF)

Insulin Detemir Is Associated With More Predictable Glycemic Control and Reduced Risk of Hypoglycemia Than NPH Insulin in Patients With Type 1 Diabetes on a Basal-Bolus Regimen With Premeal Insulin Aspart

Diabetes care, 2003-03, Vol.26 (3), p.590-596

2003

Volltextzugriff (PDF)

Evolution of Diabetes Insulin Delivery Devices

Journal of diabetes science and technology, 2010-05, Vol.4 (3), p.505-513

Selam, Jean-Louis

2010

Volltextzugriff (PDF)

Association between a Protein Polymorphism in the Start Codon of the Vitamin D Receptor Gene and Severe Diabetic Retinopathy in C-Peptide-Negative Type 1 Diabetes

The journal of clinical endocrinology and metabolism, 2005-08, Vol.90 (8), p.4803-4808

2005

Volltextzugriff (PDF)

Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study

Current medical research and opinion, 2008-01, Vol.24 (1), p.11-20

2008

Volltextzugriff (PDF)

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2015-08, Vol.314 (7), p.687

2015

Volltextzugriff (PDF)

Clinical trial of programmable implantable insulin pump for type I diabetes

Diabetes care, 1992-07, Vol.15 (7), p.877

1992

Volltextzugriff (PDF)

Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial

Advances in therapy, 2009-02, Vol.26 (2), p.194-207

2009

Volltextzugriff (PDF)

The T-786C and C774T endothelial nitric oxide synthase gene polymorphisms independently affect the onset pattern of severe diabetic retinopathy

Nitric oxide, 2005-08, Vol.13 (1), p.88-92

2005

Volltextzugriff (PDF)

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2024-01, Vol.331 (1), p.38

2024

Volltextzugriff (PDF)

Comparison of a Multiple Daily Insulin Injection Regimen (Basal Once-Daily Glargine Plus Mealtime Lispro) and Continuous Subcutaneous Insulin Infusion (Lispro) in Type 1 Diabetes

Diabetes care, 2009-07, Vol.32 (7), p.1170-1176

2009

Volltextzugriff (PDF)

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2)

Diabetes care, 2014-12, Vol.37 (12), p.3235-3243

2014

Volltextzugriff (PDF)

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

The Lancet (British edition), 2012-04, Vol.379 (9825), p.1498-1507

2012

Volltextzugriff (PDF)

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

The Lancet (British edition), 2012-04, Vol.379 (9825), p.1489-1497

2012

Volltextzugriff (PDF)

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial

Diabetic medicine, 2013-11, Vol.30 (11), p.1298-1304

2013

Volltextzugriff (PDF)

Successful treatment of insulin allergy in a type 1 diabetic patient by means of constant subcutaneous pump infusion of insulin

Diabetes care, 2003-10, Vol.26 (10), p.2961-2962

2003

Volltextzugriff (PDF)

Comparison of a Multiple Daily Insulin Injection Regimen (Basal Once-Daily Glargine Plus Mealtime Lispro) and Continuous Subcutaneous Insulin Infusion (Lispro) in Type 1 Diabetes: A randomized open parallel multicenter study

Diabetes care, 2009-07, Vol.32 (7), p.1170-1176

2009

Volltextzugriff (PDF)

Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: response to Hirshberg et al

Diabetes care, 2004-05, Vol.27 (5), p.1249

2004

Volltextzugriff (PDF)

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial

Diabetic medicine, 2013-11, Vol.30 (11), p.1293

2013

Volltextzugriff (PDF)

CSII in Europe: where are we, where are we going? An analysis of articles published in Infusystems International

Diabetes research and clinical practice, 2006-12, Vol.74, p.S123-S126

Selam, Jean Louis

2006

Volltextzugriff (PDF)

Inhaled insulin: promises and concerns

Journal of diabetes science and technology, 2008-03, Vol.2 (2), p.311-315

Sélam, Jean-Louis

2008

Volltextzugriff (PDF)

Skin collagen pentosidine and fluorescence in diabetes were predictors of retinopathy progression and creatininemia increase already 6years after punch-biopsy

Clinical biochemistry, 2016-02, Vol.49 (3), p.225-231

2016

Volltextzugriff (PDF)

Devices for insulin administration

Diabetes care, 1990-09, Vol.13 (9), p.955

1990

Volltextzugriff (PDF)

A cost-benefit comparison of intensive diabetes management with implantable pumps versus multiple subcutaneous injections in patients with type I diabetes

Diabetes care, 1994-08, Vol.17 (8), p.847

1994

Volltextzugriff (PDF)

A preliminary trial of the programmable implantable medication system for insulin delivery

The New England journal of medicine, 1989-08, Vol.321 (9), p.574

1989

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(33)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(36)
Life Sciences & Biomedicine
(32)
Science & Technology
(32)
Female
(26)
Male
(25)
Adult
(23)
Endocrinology & Metabolism
(22)
Middle Aged
(19)
Diabetes Mellitus, Type 1 - Drug Therapy
(18)
Insulin - Administration & Dosage
(17)
Biological And Medical Sciences
(14)
Diabetes
(14)
Medical Sciences
(14)
Diabetes Mellitus, Type 1 - Blood
(13)
Hypoglycemic Agents - Administration & Dosage
(11)
Glycated Hemoglobin A - Analysis
(10)
Insulin Infusion Systems
(10)
Insulin
(9)
Insulin - Therapeutic Use
(9)
Blood Glucose - Metabolism
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Lacosamide in Painful Diabetic Neuropathy: An 18-Week Double-Blind Placebo-Controlled Trial

Insulin Detemir Is Associated With More Predictable Glycemic Control and Reduced Risk of Hypoglycemia Than NPH Insulin in Patients With Type 1 Diabetes on a Basal-Bolus Regimen With Premeal Insulin Aspart

Evolution of Diabetes Insulin Delivery Devices

Association between a Protein Polymorphism in the Start Codon of the Vitamin D Receptor Gene and Severe Diabetic Retinopathy in C-Peptide-Negative Type 1 Diabetes

Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial

Clinical trial of programmable implantable insulin pump for type I diabetes

Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial

The T-786C and C774T endothelial nitric oxide synthase gene polymorphisms independently affect the onset pattern of severe diabetic retinopathy

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial

Comparison of a Multiple Daily Insulin Injection Regimen (Basal Once-Daily Glargine Plus Mealtime Lispro) and Continuous Subcutaneous Insulin Infusion (Lispro) in Type 1 Diabetes

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2)

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial

Successful treatment of insulin allergy in a type 1 diabetic patient by means of constant subcutaneous pump infusion of insulin

Comparison of a Multiple Daily Insulin Injection Regimen (Basal Once-Daily Glargine Plus Mealtime Lispro) and Continuous Subcutaneous Insulin Infusion (Lispro) in Type 1 Diabetes: A randomized open parallel multicenter study

Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: response to Hirshberg et al

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial

CSII in Europe: where are we, where are we going? An analysis of articles published in Infusystems International

Inhaled insulin: promises and concerns

Skin collagen pentosidine and fluorescence in diabetes were predictors of retinopathy progression and creatininemia increase already 6years after punch-biopsy

Devices for insulin administration

A cost-benefit comparison of intensive diabetes management with implantable pumps versus multiple subcutaneous injections in patients with type I diabetes

A preliminary trial of the programmable implantable medication system for insulin delivery

Suchergebnisse filtern